SelvitaWAR:SLV +3.27%80 FCF Yield % is 10.88 as of Jun. 29, 2026, which is 508% above its 10-year median of 1.79. GuruFocus rates WAR:SLV with a GF Score™ of 80/100 and a GF Value™ of zł58.46 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Selvita ranks better than 94.86% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Selvita's Trailing 12-Month Free Cash Flow is zł63.1 Mil, and Market Cap is zł579.9 Mil. Therefore, Selvita's FCF Yield % for today is 10.88%.
The historical rank and industry rank for Selvita's FCF Yield % or its related term are showing as below:
WAR:SLV'
s FCF Yield % Range Over the Past 10 Years
Min: -4.01 Med: 1.79 Max: 11.81
Current: 10.88
During the past 11 years, the highest FCF Yield % of Selvita was 11.81%. The lowest was -4.01%. And the median was 1.79%.
WAR:SLV's FCF Yield % is ranked better than 94.86% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.455
vs WAR:SLV: 10.88
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Selvita FCF Yield % Related Terms
Selvita FCF Yield % Historical Data
* Premium members only.
The historical data trend for Selvita's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Selvita's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Selvita FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Selvita's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Selvita's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Selvita (WAR:SLV) has a FCF Yield % of 10.88 as of Jun. 29, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Selvita and its competitors. This is 508% above median its historical median of 1.79. According to the industry distribution chart, Selvita ranks #11 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 5.1%.
Is Selvita's FCF Yield % too high?
Selvita's current FCF Yield % of 10.88 is 508% above median its 10-year median of 1.79. Based on the distribution chart, Selvita ranks #11 out of 214 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Selvita has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Selvita's FCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Selvita ranks #11 out of 214 companies for FCF Yield %. This places Selvita in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Selvita and its competitors. Selvita's current FCF Yield % is 10.88, which is 508% above median its own 10-year median of 1.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Selvita stock overvalued right now?
Based on GuruFocus' analysis, Selvita (WAR:SLV) is currently considered Significantly Undervalued. The stock's GF Value™ is zł58.46, compared to a current price of zł31.60 — trading 45.9% below its estimated fair value. The current FCF Yield % is 10.88, which is 508% above median its 10-year median of 1.79. Selvita's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Selvita (WAR:SLV), the current FCF Yield % is 10.88 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Selvita (WAR:SLV) Overvalued in 2026?
Based on GuruFocus' analysis, Selvita stock appears to be undervalued.
The current stock price of zł31.60 is trading 45.9% below its estimated GF Value™ of zł58.46.
GuruFocus considers Selvita to be Significantly Undervalued.
Key valuation signals for WAR:SLV:
FCF Yield %: 10.88 (508% above median its 10-year median of 1.79)
GF Value™: zł58.46 vs. price of zł31.60 (45.9% below fair value)
No single metric tells the full story. See the WAR:SLV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Selvita SA is a Poland based parent company of Selvita Group is one of the largest preclinical contract research organizations in Europe. It also develops bioinformatics solutions supporting innovative projects at preclinical stages. It also provides services provided to external contractors are in the field of chemistry, analytics, regulatory, biochemistry and cell biology and also the integrated research and development projects.
80GF Score
Get the complete analysis for WAR:SLV
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SLV has been successfully added to your 
